In 2016, EPAD, one of the largest public-private partnerships in AD research, began its Longitudinal Cohort Study (LCS). The study followed several people over a one-, two-, and three-year period, and collected a wide range of data to help further our understanding of the early stages of AD. Soon after ADDI’s launch in 2020, EPAD made access to this LCS data available to researchers through the AD Workbench. This includes the final longitudinal data from over 2,000 participants – and incudes a wide range of cognitive, clinical, neuroimaging, and biomarker data.

To continue this path of discovery, ADDI is excited to announce this data source has now been enriched with genomic data. This is an important step in continuing to share the EPAD LCS data in the long-term and ensuring that this valuable resource is used by the research community to generate as much knowledge as possible. ADDI and its partners like EPAD are committed to fostering collaboration, including greater access to data, so researchers can accelerate the development of new and more effective treatments and cures for AD and related dementias.

“This most recent release with genomic data from the EPAD LCS will provide new knowledge to the global research community and marks another major milestone for EPAD. We expect that in the months ahead, new data being collected from further research/analysis of EPAD samples and other programmes run within the Edinburgh Dementia Prevention will utilise the AD workbench making AD data findable, accessible, interoperable and reusable (according to the FAIR principles)”, said Craig Ritchie, Project Coordinator of the EPAD project.

“We’re grateful for the growth of our partnership with EPAD. Access to genomic data will help ADDI in our effort to promote knowledge sharing across Alzheimer’s disease research, and to be an indispensable resource for researchers who are tackling these problems,” said Dr. Tetsu Maruyama, Executive Director of ADDI.

For more information about ADDI, please visit: https://www.alzheimersdata.org/

For more information about EPAD, please visit: https://www.ep-ad.org/

Date 03.17.2022
Source ADDI